Special Authority Forms
General Practitioners and specialists can download individual forms for making Special Authority applications from this page.
Alternatively, all forms are available in one indexed document, Special Authority Forms, May 2008 (154 pages, 434 KB).
Sort by Therapeutic Group or Form Title (Chemical Name)
Alimentary Tract and Metabolism
From page 24 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0490 – Acarbose (1 page, 2 KB)
- SA0264 – Alpha Tocopheryl Acetate (1 page, 2 KB)
- SA0698 – Budesonide – Cap 3 mg Controlled Release (1 page, 3 KB)
- SA0834 – Insulin Glargine (1 page, 3 KB)
- SA0891 – Macrogol 3350 (1 page, 2 KB)
- SA0859 – Pioglitazone (2 pages, 6 KB)
- SA0841 – Ursodeoxycholic Acid – Cap 300 mg (1 page, 3 KB)
Blood and Blood Forming Organs
From page 39 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0788 – Atorvastatin (1 page, 4 KB)
- SA0867 – Clopidogrel (3 pages, 8 KB)
- SA0648 – Dipyridamole Tab 25 mg (1 page, 3 KB)
- SA0649 – Dipyridamole Tab long-acting 150 mg (1 page, 3 KB)
- SA0626 – Erythropoietin Alpha (1 page, 3 KB)
- SA0851 – Erythropoietin Beta (1 page, 3 KB)
- SA0796 – Ezetimibe (2 pages, 5 KB)
- SA0826 – Ezetimibe with Simvastatin: Vytorin (1 page, 4 KB)
- SA0849 – Pravastatin (1 page, 2 KB)
Cardiovascular System
From page 53 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0862 – Candesartan; and Losartan (1 page, 3 KB)
- SA0361 – Midodrine (1 page, 3 KB)
- SA0256 – Perhexiline Maleate (1 page, 2 KB)
Dermatologicals
From page 63 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)Genito-Urinary System
From page 72 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)Hormone Preparations - Systemic Excluding Contraceptive Hormones
From page 77 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0797 – Alendronate: Alendronate Tab 70 mg (1 page, 4 KB)
- SA0835 – Buserelin (2 pages, 6 KB)
- SA0175 – Cabergoline (1 page, 2 KB)
- SA0090 – Desmopressin – Inj 4 µg per ml, 1 ml (1 page, 2 KB)
- SA0839 – Goserelin (2 pages, 6 KB)
- SA0755 – GROWTH HORMONE THERAPY GUIDELINES (15 pages, 670 KB)
- SA0312 – Hormone Replacement Therapy – Systemic (1 page, 3 KB)
- SA0837 – Leuprorelin (2 pages, 6 KB)
- SA0091 – Pamidronate Disodium (1 page, 2 KB)
Infections - Agents for Systemic Use
From page 88 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0829 – Adefovir dipivoxil (1 page, 3 KB)
- SA0779 – Antiretrovirals (2 pages, 6 KB)
- SA0657 – Clarithromycin (1 page, 3 KB)
- SA0845 – Enfuvirtide (1 page, 3 KB)
- SA0832 – Lamivudine (2 pages, 6 KB)
Musculo-skeletal System
From page 100 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0812 – Adalimumab (2 pages, 7 KB)
- SA0291 – Anti-inflammatory Non Steroidal Drugs (NSAIDs) (1 page, 2 KB)
- SA0868 – Etanercept (1 page, 4 KB)
- SA0635 – Leflunomide (1 page, 2 KB)
Nervous System
From page 105 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0863 – Buspirone Hydrochloride (1 page, 2 KB)
- SA0907 – Dexamphetamine Sulphate (3 pages, 8 KB)
- SA0435 – Domperidone (1 page, 2 KB)
- SA0743 – Fentanyl patches (1 page, 2 KB)
- SA0873 – Gabapentin (2 pages, 6 KB)
- SA0727 – Hyoscine (Scopolamine) (1 page, 2 KB)
- SA0906 – Lignocaine with Prilocaine (1 page, 2 KB)
- SA0908 – Methylphenidate Hydrochloride (3 pages, 8 KB)
- SA0864 – Mianserin Hydrochloride (1 page, 2 KB)
- SA0909 – Naltrexone (1 page, 3 KB)
- SA0741 – Olanzapine tabs (1 page, 3 KB)
- SA0739 – Olanzapine wafers (1 page, 2 KB)
- SA0887 – Ondansetron (1 page, 2 KB)
- SA0792 – Risperidone microspheres (1 page, 3 KB)
- SA0794 – Risperidone orally disintegrating tablets (1 page, 3 KB)
- SA0874 – Topiramate (1 page, 3 KB)
- SA0789 – Venlafaxine (1 page, 3 KB)
- SA0875 – Vigabatrin (2 pages, 6 KB)
Oncology Agents and Immunosuppressants
From page 127 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0879 – Anagrelide Hydrochloride (1 page, 3 KB)
- SA0810 – Anastrozole (1 page, 3 KB)
- SA0643 – APPLICATION FOR IMATINIB MESYLATE FOR TREATMENT OF CHRONIC MYELOID LEUKAEMIA OR GASTROINTESTINAL STROMAL TUMOUR (GIST) (3 pages, 40 KB)
- SA0869 – Capecitabine (1 page, 3 KB)
- SA0470 – Cyclosporin A (2 pages, 5 KB)
- SA0880 – Docetaxel (2 pages, 4 KB)
- SA0877 – Gemcitabine Hydrochloride (1 page, 3 KB)
- SA0784 – Interferon Alpha-2A with ribavirin (1 page, 2 KB)
- SA0878 – Irinotecan (1 page, 2 KB)
- SA0811 – Letrozole (1 page, 3 KB)
- SA0855 – Multiple Sclerosis treatments, Initial Application for beta-interferon or glatiramer acetate (8 pages, 183 KB)
- SA0855 – Multiple Sclerosis treatments, Renewal Application form for beta-interferon or glatiramer acetate (5 pages, 171 KB)
- SA0893 – Mycophenolate (1 page, 2 KB)
- SA0563 – Octreotide (somatostatin analogue) (1 page, 3 KB)
- SA0900 – Oxaliplatin (1 page, 3 KB)
- SA0802 – Pegylated Interferon Alpha-2a (1 page, 3 KB)
- SA0846 – Pegylated Interferon Alpha-2b with Ribavirin (1 page, 3 KB)
- SA0884 – Rituximab (2 pages, 4 KB)
- SA0866 – Sirolimus (Rapamune) (1 page, 2 KB)
- SA0669 – Tacrolimus (1 page, 2 KB)
- SA0831 – Temozolomide (1 page, 2 KB)
- SA0882 – Thalidomide (1 page, 3 KB)
- SA0885 – Trastuzumab (1 page, 3 KB)
- SA0901 – Vinorelbine (1 page, 3 KB)
Respiratory System and Allergies
From page 146 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0838 – Budesonide with eformoterol (Symbicort); and Fluticasone with Salmeterol (Seretide) (1 page, 3 KB)
- SA0611 – Dornase Alfa - Entry and Stopping Criteria for Treatment (16 pages, 384 KB)
- SA0872 – Tiotropium Bromide (1 page, 3 KB)
Sensory Organs
From page 153 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0895 – Pilocarpine – Eye drops 2% single dose (1 page, 2 KB)
Various
From page 158 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)Extemporaneously Compounded Preparations and Galenicals
From page 163 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)Special Foods
From page 166 of the Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)- SA0585 – Adult Products High Calorie: Two Cal HN (2 pages, 5 KB)
- SA0581 – Carbohydrate and Fat: Duocal Super Soluble Powder (2 pages, 4 KB)
- SA0588 – CORD Products: Pulmocare (1 page, 3 KB)
- SA0594 – Diabetic Products: Diasip, Diason, Glucerna, Glucerna RTH, Resource Diabetic, Resource Diabetic RTH (1 page, 3 KB)
- SA0615 – Fat Modified Products: Monogen (1 page, 2 KB)
- SA0899 – Fat: Calogen, Liquigen, MCT oil (Nutricia) (2 pages, 4 KB)
- SA0732 – Foods used for Homocystinuria or maple syrup urine disease: Maxamaid MSUD, Maxamum MSUD, MSUD Aid, XMET Maxamum (1 page, 2 KB)
- SA0589 – High Protein Products: Fortimel (1 page, 3 KB)
- SA0604 – Infant Formulae – For Milk Intolerance: Delact, Infasoy, Karicare Goats Milk Infant Formula (1 page, 3 KB)
- SA0601 – Infant Formulae – For Williams Syndrome: Locasol (1 page, 2 KB)
- SA0757 – Infant Formulae – Lactose Intolerance and Cows’ Milk Protein Intolerance: Karicare All Ages (1 page, 2 KB)
- SA0600 – Multivitamin And Mineral Supplements For Inborn Errors Of Metabolism: Ketovite, Ketovite Syrup, Paediatric Seravite (1 page, 2 KB)
- SA0582 – Protein: Promod, Protifar 90 (1 page, 2 KB)
- SA0587 – Renal Products: Nepro (vanilla), NovaSource Renal, Nutrison Concentrated RTH, Renilon 7.5 (1 page, 3 KB)
- SA0592 – Specialised And Elemental Products: Alitraq, Elemental 028 Extra, Peptisorb RTH, Vital HN, Vivonex TEN (1 page, 3 KB)
Data
Active Special Authority numbers for atorvastatin (Lipitor) (2 pages, 489 KB) – listing of active Special Authority approvals for atorvastatin (Lipitor) from 1 June 2004 (other than approvals under the new criteria).
Special Authority approvals for atorvastatin (Lipitor) (40 pages, 828 KB)) – from 1 June 2004 (other than approvals under the new criteria).
Page updated on 01 May 2008
Linked documents
Special Authority Forms, May 2008 (154 pages, 434 KB)
SPECIAL AUTHORITY FORMS May 2008 Contents Panel Approvals… 4 Alimentary Tract and Metabolism … 5 Blood and Blood Forming Organs…. 14 Cardiovascular System ….. 27 Genito-Urinary System… 32 Hormone Preparations - Systemic Excluding Contraceptive Hormones… 34 Infections - Agents for…
Pharmaceutical Schedule, May 2008 (224 pages, 1344 KB)
Introducing PHARMAC 2 May 2008 Volume 15 Number 1 Editors Linda Wellington & Kaye Wilson email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 14, Cigna House 40 Mercer Street PO Box 10 254 Wellington Freephone…
SA0855 – Multiple Sclerosis treatments, Initial Application for beta-interferon or glatiramer acetate (8 pages, 183 KB)
INITIAL APPLICATION FOR FUNDING OF BETA-INTERFERON OR GLATIRAMER ACETATE Please send applications to: The Co-ordinator MSTAC PHARMAC P O Box 10-254 WELLINGTON Phone: 04 460 4990 Facsimile: 04 916 7571 Email: mstaccoordinator@pharmac.govt.nz Applications must be complete and accompanied by all…
SA0855 – Multiple Sclerosis treatments, Renewal Application form for beta-interferon or glatiramer acetate (5 pages, 171 KB)
RENEWAL APPLICATION FOR FUNDING OF BETA-INTERFERON OR GLATIRAMER ACETATE For patients who are currently being treated with beta-interferon or glatiramer acetate (with New Zealand government funding) Please send applications to: The Co-ordinator MSTAC PHARMAC P O Box 10-254 WELLINGTON Phone:…
Active Special Authority numbers for atorvastatin (Lipitor) (2 pages, 489 KB)
By now you should have received information regarding the changes in access to atorvastatin being implemented from 1 June 2004. In essence these changes will result in patients that are on a dose below 40 mg of atorvastatin per day having their Special Authority cancelled.
Special Authority approvals for atorvastatin (Lipitor) (40 pages, 828 KB)
Listing of active Special Authority approvals for atorvastatin (Lipitor) from 1 June 2004 (other than approvals under the new criteria).